

## **Carin Hanna Gribetz, M.D.**

**Education:** **Cornell University Medical College, New York, NY**  
Doctor of Medicine, May 2000

**University of Pennsylvania, Philadelphia, PA**  
Magna Cum Laude, Bachelor of Arts, Biological Basis of Behavior, May 1996

**Postdoctoral Training:** **Mount Sinai Medical Center**  
**New York, NY**

Chief Resident, Department of Dermatology	7/05-6/06
Resident, Department of Dermatology	7/03-6/06
Fellow, Dermatopharmacology	7/01-6/03
Intern, Department of Internal Medicine	7/00-6/01

**Professional Appointment:** **Mount Sinai School of Medicine** 12/06-present  
Department of Dermatology  
Assistant Clinical Professor of Dermatology

### **Medical and Cosmetic Dermatology Practice:**

Carin H. Gribetz, M.D., P.C.  
108 East 86<sup>th</sup> Street, Suite 1N  
New York, New York 10028

### **Medical Licensure and Certification:**

Certified by the American Board of Dermatology 8/06-present  
New York State License #222165

### **Professional Associations:**

Fellow of the American Academy of Dermatology  
Manhattan Metropolitan Dermatologic Society  
Dermatologic Society of Greater New York  
Independent Doctors of New York  
Skin Cancer Foundation

## **Professional Publications/Presentations:**

WS Fuchs, MD; MR Young; BS Fuchs; RR Blum, MD; GK Singer, BS; DK Stern, MD; **CH Gribetz, MD**; J Zeichner, MD; PO Emanuel, MD; J Tan, MD; RG Phelps, MD; SE Brodie MD, PhD; MG Lebowhl, MD. Oral phosphate binders in the treatment of pseudoxanthoma elasticum. Poster to be presented at the Association for Research in Vision and Ophthalmology. 2007

**Gribetz C**, Blum R, Brady C, Cohen S, Lebowhl M. Safety and efficacy of an extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. *J Am Acad Dermatol.* 2005 Jul;53(1):73-5

**Gribetz C**, Ling M, Lebowhl M, et al. Efficacy and Safety of Pimecrolimus 1% Cream in the Treatment of Intertriginous Psoriasis: a double-blind randomized study. *J Am Acad Dermatol.* 2004 Nov;51(5):731-8.

**Gribetz C**, Blum R, Brady C, Cohen S, Lebowhl M. Safety and efficacy of an extended 16-week course of alefacept in the treatment of chronic plaque psoriasis

Poster presented at the 62<sup>nd</sup> annual meeting of the American Academy of Dermatology, Feb 6-11, 2004, Washington, DC.

Oral Presentation at Canadian Dermatology Association Meeting, Quebec City June 2005

Oral Presentation at the New York Academy of Medicine, June 2005

**Gribetz C**, Blum R, Lamba S, Lebowhl M. A Pilot Study Evaluating the use of Hydrocortisone Butyrate 0.1% Lipocream in Conjunction with Tacrolimus 0.1% Ointment in the Treatment of Atopic Dermatitis. Poster presented at the American Academy of Dermatology Summer Meeting, July 2003, Chicago, IL.

**Gribetz C**, Lebowhl M. Clearing Psoriasis: A New Era of Optimism. *Contemporary Dermatology* March 2003; Volume 1, Number 1

Koo J., Menter A., Lebowhl M, Kozma C, **Gribetz C**, et al. The Relationship Between Quality of Life and Disease Severity: Results From a Large Cohort of Mild, Moderate, and Severe Psoriasis Patients. Poster presented at the 61<sup>st</sup> annual meeting of the American Academy of Dermatology, March 21-26, 2003, San Francisco, CA.

**Gribetz C**. Experience With Topical Anesthetics: A Review. Poster presented at Annual Caribbean Dermatology Symposium, January 2003.

**Endzweig Gribetz C**, Brady C, Lynde C, Sibbald D, Lebowhl M. Drug Interactions in Psoriasis: The Pros and Cons of Combining Topical Therapies. *J Cutan Med Surg* 2002 May-Jun;6(3 Suppl):12-16

**Endzweig CH**, Lebowhl M. Olux™ Foam: A Cosmetically Appealing Delivery System for the Treatment of Psoriasis. *Cosmetic Dermatology* Nov 2001;14(11): 13-15

**Endzweig CH**, Lazinsky A. Combination Systemic Therapy in the Treatment of Psoriasis. Psoriasis Foundation. National Psoriasis Foundation Winter 2000; 6(4):1-4

**Endzweig CH**, Strauss E, Murphy F, Rao BK. A Case of Cutaneous Mycobacterium chelonae abscessus in a Renal Transplant Patient. J Cutan Med Surg Jan 2001; 5(1):28-32

Nichols KT, **Endzweig CH**, Sapiden A. Efficacy Between two Acne Cleansers Among Patients with Acne. Poster presented at American Academy of Dermatology Meeting, San Francisco, Feb 2000

Rao BK, **Endzweig CH**, Kagen M, Kriegel D, Freeman RG. Wrinkling Due to Mid-Dermal Elastolysis: Presentation of Two Cases and Literature Review. J Cutan Med Surg 2000; 4(1):40-4

### **Research Experience:**

The Mount Sinai School of Medicine, New York, NY  
Department of Dermatology, Clinical Trials, July 2001-June 2003

#### Principal Investigator:

- Onychomycosis (Oral)- Novartis, 2003
- Atopic dermatitis (Topical)- Ferndale, 2003
- Acne Study (Topical)- Connetics, 2003
- Psoriasis and Atopic Dermatitis (Apheresis)-Otsuka pharmaceuticals, 2002
- Inverse Psoriasis Study (Topical) –Novartis, 2002
- Psoriasis Study (Oral therapy)- Biogen, 2002
- Psoriasis Study (Intravenous Infusion)- Centacor, 2002
- Psoriasis Study (Subcutaneous Injection)- Immunex, 2002

#### Co-Investigator:

- Psoriasis (Intramuscular Injection)- Biogen, 2003
- Psoriasis (Subcutaneous Injection) – Xoma, 2003
- Psoriasis (Subcutaneous injection)- Genentech, 2003
- Atopic dermatitis (Topical) – Fujisawa, 2003
- Inverse Psoriasis Study (Topical) – Fujisawa, 2002
- Atopic dermatitis-Novartis, 2002
- Atopic dermatitis, pediatric- Novartis, 2002
- Psoriasis Study (Oral therapy) Allergan, 2002
- Psoriasis Study (LASER)-Candela, 2002
- Psoriasis Study (Intravenous Injection)- Biogen, 2001
- Actinic Keratosis (Topical) 3M, 2001
- Psoriasis Study (Oral therapy) GlaxoSmithKline, 2001
- Psoriasis Study (Subcutaneous Injection) – Medimmune, 2001
- Psoriasis Study (Intravenous Infusion)-Abgenix, 2001
- Psoriasis Study (Oral therapy)-Boehringer Ingelheim, 2001

Psoriasis Study (Intravenous Infusion)- IDEC, 2001  
Psoriasis Study (Intravenous Infusion) – Protein Design Labs, 2001  
Intertriginous Psoriasis Study – Fujisawa, 2001  
Atopic Dermatitis Study – Fujisawa, 2001  
Psoriasis Study – Allergan, 2001  
Renova Study (Skin Types I-III) – Johnson & Johnson, 2000-2001  
Renova Study (Skin Types IV-VI) – Johnson & Johnson, 2000-2001  
Male Pattern Baldness – Merck, 2000-2001  
Psoriatic Arthritis – Immunex, 2000-2001  
Psoriasis Study – Genentech, 2000-2001  
Psoriasis Study – Protein Design Labs, 2001  
Psoriasis Study (Topical)– Novartis, 2001  
Tinea Pedis Study (Topical)– Novartis, 2001  
Scalp Psoriasis Study (Topical)– Galderma, 2001  
Psoriasis Study (Topical)– Connetics, 2001